Shareholding disclosure

Newron Pharmaceuticals SpA

Declared position

10.66%

Threshold

Crossed downwards

Timeline

Published

30.11.2019

Transaction

25.11.2019

Voting rights breakdown

Voting rights acquired0%

Voting rights sold10.66%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAJBT00038

Beneficial owner

Newron Pharmaceuticals SpA

Declared address

Newron Pharmaceuticals SpA, 20091 Bresso (MI)

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A.30.11.2019TAJBT00038

Disclosure summary

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A. on the disposal side, published by SIX Exchange Regulation on 30.11.2019, at 10.66% of voting rights. Notice category: Single shareholder.

Disclosed position

10.66%

Voting rights sold

Voting rights acquired0%

Voting rights sold10.66%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A., published on 30.11.2019.

Publication date30.11.2019

Transaction date25.11.2019

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerNewron Pharmaceuticals SpA

Declared addressNewron Pharmaceuticals SpA, 20091 Bresso (MI)

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold10.66%

Below threshold0%

ExchangeXSWX

Notification IDTAJBT00038

Source: SIX Exchange Regulation · Publication date: 30.11.2019

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open